ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för crizotinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

23 träffar

Bibliografisk träff 2014-02-20

Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer.

Ji C, Zhang L, Cheng Y, Patel R, Wu H, Zhang Y, Wang M, Ji S, Belani CP, Yang JM, Ren X.

Cancer Biol Ther · research-article; journal article · DOI 10.4161/cbt.28162

Bibliografisk träff 2014-02-01

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small-cell lung cancer.

Tibaldi C.

Pharmacogenomics · journal article · DOI 10.2217/pgs.13.236

Bibliografisk träff 2014-02-01

Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.

Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, Messa C, Guerra L, Giudici G, Sala E, Mussolin L, Deeren D, King MH, Steurer M, Ordemann R, Cohen AM, Grube M, Bernard L, Chiriano G, Antolini L, Piazza R.

J Natl Cancer Inst · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1093/jnci/djt378

Bibliografisk träff 2014-01-08

Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma.

Hamedani FS, Cinar M, Mo Z, Cervania MA, Amin HM, Alkan S.

Leuk Res · research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.leukres.2013.12.027

Bibliografisk träff 2013-11-01

Crizotinib.

Författaruppgift saknas

Prescrire Int · journal article

Bibliografisk träff 2013-04-01

Crizotinib: A comprehensive review.

Sahu A, Prabhash K, Noronha V, Joshi A, Desai S.

South Asian J Cancer · review-article; review; journal article · DOI 10.4103/2278-330x.110506

Bibliografisk träff 2012-07-01

Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.

Zhou WJ, Zhang X, Cheng C, Wang F, Wang XK, Liang YJ, To KK, Zhou W, Huang HB, Fu LW.

Br J Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/j.1476-5381.2012.01849.x

Bibliografisk träff 2012-05-09

Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.

Yano S, Takeuchi S, Nakagawa T, Yamada T.

Cancer Sci · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1111/j.1349-7006.2012.02279.x

Bibliografisk träff 2012-04-01

The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation.

Pillai RN, Ramalingam SS.

Curr Oncol Rep · research support, non-u.s. gov't; review; journal article · DOI 10.1007/s11912-012-0213-4

Bibliografisk träff 2012-03-23

The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer.

Galetta D, Rossi A, Pisconti S, Colucci G.

Expert Opin Ther Targets · review; journal article · DOI 10.1517/14728222.2011.642372

Bibliografisk träff 2012-03-06

ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.

Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.

Eur J Cancer · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejca.2012.02.001

Bibliografisk träff 2012-03-03

ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.

Ahn HK, Han B, Lee SJ, Lim T, Sun JM, Ahn JS, Ahn MJ, Park K.

Lung Cancer · research support, non-u.s. gov't; journal article; case reports · DOI 10.1016/j.lungcan.2012.02.003

Bibliografisk träff 2012-02-07

Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis.

Yauch RL, Settleman J.

Curr Opin Genet Dev · review; journal article · DOI 10.1016/j.gde.2012.01.003

Bibliografisk träff 2012-02-01

Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.

Ou SH.

Expert Rev Anticancer Ther · review; journal article · DOI 10.1586/era.11.186

Bibliografisk träff 2012-02-01

Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.

Lovly CM, Pao W.

Sci Transl Med · comment; research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1126/scitranslmed.3003728

Bibliografisk träff 2012-01-26

Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.

Camidge DR, Theodoro M, Maxson DA, Skokan M, O'Brien T, Lu X, Doebele RC, Barón AE, Varella-Garcia M.

Cancer · research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/cncr.27411

Bibliografisk träff 2012-01-25

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, Engelman JA.

Sci Transl Med · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1126/scitranslmed.3003316

Bibliografisk träff 2012-01-10

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR.

Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-11-2906

Bibliografisk träff 2012-01-03

ROS1 rearrangements define a unique molecular class of lung cancers.

Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ.

J Clin Oncol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1200/jco.2011.35.6345

Bibliografisk träff 2012-01-01

Crizotinib: in locally advanced or metastatic non-small cell lung cancer.

Curran MP.

Drugs · review; journal article · DOI 10.2165/11207680-000000000-00000

Bibliografisk träff 2011-12-01

Crizotinib.

Shaw AT, Yasothan U, Kirkpatrick P.

Nat Rev Drug Discov · news · DOI 10.1038/nrd3600

Bibliografisk träff 2011-11-30

Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.

Yamazaki S, Vicini P, Shen Z, Zou HY, Lee J, Li Q, Christensen JG, Smith BJ, Shetty B.

J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.111.188870

Bibliografisk träff 2011-06-01

The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model.

Sampson ER, Martin BA, Morris AE, Xie C, Schwarz EM, O'Keefe RJ, Rosier RN.

J Bone Miner Res · research support, non-u.s. gov't; journal article · DOI 10.1002/jbmr.336